Mylan Talks Up Prospects For Becoming Leader In Generic Injectables

The generic drug maker has set ambitious price targets for its stock over the next five years based on recently acquired assets and some risky generic drug launches. Analysts are concerned the company is putting too much faith in high-risk projects.